With KPA being a small pharma company. Why won’t corporate listen to sales reps? Too prideful?

Quote


Hmmm. Manager or rep writing about a "day in the life of a sales rep" ? Correct me if I'm wrong..you're typically a rep before you become a handler. Either way, why $hit on a rep like that?
 
anonymous said:
Fuck all you assholes posting here negatively about JM (quite possibly one person as well.) That dude bleeds Kowa and works his ass off for all of YOU! Think about this - he is the Chief Commercial Officer of a multi million dollar pharmaceutical company and the loser posters here on CF are fucking SALES REPRESENTATIVES with an opinion. BIG fucking difference. He works his ass off for Kowa to be successful and gets shit on by REPRESENTATIVES who mustle type into an anonymous forum where they can’t be identified. I am actually embarrassed that I am posting here because folks who post here are unhappy losers - but this will be my 1st and last post.
So back the fuck off JM because all he wants to do is provide a great place to work for everyone WHO WANTS TO BE HERE. If you don’t want to be here - fucking leave….but back off JM. YUDAMAN Jeff - and never forget it!!!
Click to expand...

Nice to see Jeff or at least his butt buddy, Jason (tennis pro), has time to spend in CF. Maybe they should spend a little time trying to navigate the world of co-promotion agreements, or copay cards or marketing of a pain med, or anything that could save their jobs. Jeff has always had a Napoleonic complex and his attitude continues to worsen as things do. He no longer has a place to hide. Anyone who has been around him has noticed and I have. "Jeff or Jason" will be back they are like trolls on Twitter they can't help themselves. LOL
 
It was a major mistake to stop promoting Livalo over a year ago. Any first-year university marketing student could have made better decisions. Hmm, stop promoting a drug that pays all the bills and brings in $500+ millions in sales every year with 18 months left on its patent life. Why did Kowa even bother to get the 6-month patent extension for their pediatric indication? The launch of Seglentis has to have been the worst drug launch in the history of pharmaceuticals. Delayed launch, pharmacy stocking issues, co-pay card issues, marketing issues, un-inspiring detail pieces, confusing directives from management, etc. The reason Livalo’s launch was successful, was due to Lilly being involved in the launch. So many good Sales Representatives and District Managers have left Kowa due to the bad decisions by upper management. Kowa’s field sales force turn-over has to be one of the highest in the industry. Down at 40+ sales reps since the launch of Seglentis, and more are leaving or at least looking at other opportunities. Kowa has to stop the bleeding of its sales force if it wants to have future sales co-promotes. In the end, Japan will have the final word on who stays employed on the leadership team.
 
anonymous said:
It was a major mistake to stop promoting Livalo over a year ago. Any first-year university marketing student could have made better decisions. Hmm, stop promoting a drug that pays all the bills and brings in $500+ millions in sales every year with 18 months left on its patent life. Why did Kowa even bother to get the 6-month patent extension for their pediatric indication? The launch of Seglentis has to have been the worst drug launch in the history of pharmaceuticals. Delayed launch, pharmacy stocking issues, co-pay card issues, marketing issues, un-inspiring detail pieces, confusing directives from management, etc. The reason Livalo’s launch was successful, was due to Lilly being involved in the launch. So many good Sales Representatives and District Managers have left Kowa due to the bad decisions by upper management. Kowa’s field sales force turn-over has to be one of the highest in the industry. Down at 40+ sales reps since the launch of Seglentis, and more are leaving or at least looking at other opportunities. Kowa has to stop the bleeding of its sales force if it wants to have future sales co-promotes. In the end, Japan will have the final word on who stays employed on the leadership team.
Click to expand...
 
anonymous said:
It was a major mistake to stop promoting Livalo over a year ago. Any first-year university marketing student could have made better decisions. Hmm, stop promoting a drug that pays all the bills and brings in $500+ millions in sales every year with 18 months left on its patent life. Why did Kowa even bother to get the 6-month patent extension for their pediatric indication? The launch of Seglentis has to have been the worst drug launch in the history of pharmaceuticals. Delayed launch, pharmacy stocking issues, co-pay card issues, marketing issues, un-inspiring detail pieces, confusing directives from management, etc. The reason Livalo’s launch was successful, was due to Lilly being involved in the launch. So many good Sales Representatives and District Managers have left Kowa due to the bad decisions by upper management. Kowa’s field sales force turn-over has to be one of the highest in the industry. Down at 40+ sales reps since the launch of Seglentis, and more are leaving or at least looking at other opportunities. Kowa has to stop the bleeding of its sales force if it wants to have future sales co-promotes. In the end, Japan will have the final word on who stays employed on the leadership team.
Click to expand...
 
anonymous said:
It was a major mistake to stop promoting Livalo over a year ago. Any first-year university marketing student could have made better decisions. Hmm, stop promoting a drug that pays all the bills and brings in $500+ millions in sales every year with 18 months left on its patent life. Why did Kowa even bother to get the 6-month patent extension for their pediatric indication? The launch of Seglentis has to have been the worst drug launch in the history of pharmaceuticals. Delayed launch, pharmacy stocking issues, co-pay card issues, marketing issues, un-inspiring detail pieces, confusing directives from management, etc. The reason Livalo’s launch was successful, was due to Lilly being involved in the launch. So many good Sales Representatives and District Managers have left Kowa due to the bad decisions by upper management. Kowa’s field sales force turn-over has to be one of the highest in the industry. Down at 40+ sales reps since the launch of Seglentis, and more are leaving or at least looking at other opportunities. Kowa has to stop the bleeding of its sales force if it wants to have future sales co-promotes. In the end, Japan will have the final word on who stays employed on the leadership team.
Click to expand...

agreed! WHY direct all reps to suddenly stop selling Livalo with 18 months left of branded life……AND then direct all reps to spend months trying to stock all pharmacy’s for SEG. THEN find out that’s not working AND change directions again and tell reps to go chase ALL reversals. NOW upper management wants reps to focus on BLINKRX and protecting the Livalo brand…upper management needs to have their own evaluation. Livalo could have exceeded all time high in sales but upper management wanted reps to go try and stock pharmacy to find out later pharmacy’s aren’t going to stock SEG unless they see a script…
 
anonymous said:
Kowa has just one person to blame for what happened to Kowa. His name is Jeff Moore. Once he was elevated to VP, a title he didn't allow his successor to have, the culture was lost. Jeff surrounded himself with yes men who know less about pharma than I have forgotten. Can you say "Tennis Pro Jason" for example? Jeff pulls all the strings and once Lou left and he promoted himself while still running everything else he was truly outside his depth. Livalo will be generic in November. It paid all the bills. They lose money on EVERY Seglentis script filled. If Blink doesn't start driving thousands of scripts soon, all that leadership group is gone. Have you not noticed no one is getting hired? They didn't even rehire the RD is the west? There are 40 reps fewer than they were at Seglentis launch, and that launch is less than 5% to expectations!

K-877 was supposed to be the next Livalo when that fell through they had no back up plan. Kowa will survive, but it may be as an ophthalmology company. If you expect it to get better or Seglentis to somehow turn around with that brain trust in place, then you are whistling past the graveyard. Culture and leadership matter, and Kowa has NONE. Polish that resume and start looking. Lots are leaving, don't be last. It will get worse as revenue continues to shrink. It isn't 280 reps all being bad that got them here.
Click to expand...

upper management is incompetent. Did they have brand launch experience? They thought they could do it all by themselves. Cost Kowa hundreds of millions in loss revenue on Livalo spending a whole year telling reps to go try to “fill” all pharmacy’s with SEG. Which pharmacy’s WILL NOT unless they see a script. They still wanted reps to chase pharmacy’s on reversals and try to convince them to order a bottle. Even when the co-pay cars wouldn’t go through. Such a mess. It’s been going on for a year now. While reps could have been focusing on Livalo MORE to reach all time high on revenue before it goes generic which upper management ignored Livalo for over a year. Now they want reps to protect the Livalo brand with BLINKRX after neglecting Livalo Doctors for over a year…
 
anonymous said:
agreed! WHY direct all reps to suddenly stop selling Livalo with 18 months left of branded life……AND then direct all reps to spend months trying to stock all pharmacy’s for SEG. THEN find out that’s not working AND change directions again and tell reps to go chase ALL reversals. NOW upper management wants reps to focus on BLINKRX and protecting the Livalo brand…upper management needs to have their own evaluation. Livalo could have exceeded all time high in sales but upper management wanted reps to go try and stock pharmacy to find out later pharmacy’s aren’t going to stock SEG unless they see a script…
Click to expand...
I stan for this! Like you said, would love to know the Why from upper management on their decision to change directions with Livalo and SEG throughout the last 18 months.
 


Write your reply...
Top Bottom
Back
Quote